Check-Cap (MBAI)

The company’s approach is intended to address a major barrier in colorectal screening: patient reluctance to undergo conventional colonoscopy preparation and invasive procedures. C-Scan is designed to be swallowed, move naturally through the digestive system, and be excreted without the need for retrieval. Data from the capsule is collected externally, with the aim of producing three-dimensional imaging information that can help physicians detect relevant findings in the colon.

Check-Cap’s technology sits at the intersection of medical imaging, capsule endoscopy, and preventive oncology. Colorectal cancer is one of the most common cancers worldwide, and early detection can significantly improve treatment outcomes. A screening option that avoids bowel preparation and sedation could broaden participation if it demonstrates sufficient safety, accuracy, and clinical utility.

The company’s operations are based in Israel, while its commercial ambitions have included major healthcare markets such as the United States, Europe, Israel, and Japan. As a clinical-stage diagnostics business, Check-Cap’s value is closely linked to regulatory progress, clinical trial results, reimbursement prospects, manufacturing readiness, and the willingness of healthcare systems to adopt new screening technologies. Investors should view it as a development-stage medical technology company with potentially differentiated intellectual property, but also with the execution and approval risks typical of companies that have not yet reached broad commercialisation.